Is tezepelumab more than just an anti-eosinophil drug?
Adil Adatia, Mustafaa Wahab, Imran Satia
Abstract
Tezepelumab significantly reduces airway eosinophilia, which is the most likely mechanism by which it reduces the risk of asthma exacerbation in patients with moderate–severe asthma, but has little effect on airway hyperresponsiveness to mannitol <https://bit.ly/3xnt5sS>
Topics & Concepts
MedicineAirway hyperresponsivenessExacerbationAsthmaEosinophilEosinophiliaAsthma exacerbationsAirwayDrugBronchial hyperresponsivenessImmunologyInternal medicinePharmacologyAnesthesiaLungRespiratory diseaseAsthma and respiratory diseasesRespiratory and Cough-Related ResearchChronic Obstructive Pulmonary Disease (COPD) Research